These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11426792)

  • 61. Coronary artery stenting in MI and Abciximab: a necessary combination?
    Block PC
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):180. PubMed ID: 9377647
    [No Abstract]   [Full Text] [Related]  

  • 62. Comparison between glycoprotein IIb/IIIa blockade and distal protection device for the restoration of myocardial perfusion during percutaneous coronary intervention for acute myocardial infarction.
    Mak KH; Phay C; Wong A; Kwok V; Tan KS; Lau KW; Koh TH
    J Invasive Cardiol; 2004 Dec; 16(12):694-8. PubMed ID: 15596872
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions.
    Best PJ; Lennon R; Gersh BJ; Ting HH; Rihal CS; Bell MR; Herzog CA; Holmes DR; Berger PB
    Am Heart J; 2003 Aug; 146(2):345-50. PubMed ID: 12891206
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
    Patel SS; Rana H; Mascarenhas DA
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):89-93. PubMed ID: 18413897
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
    Simoons ML;
    Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Sabatine MS; Jang IK
    Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 72. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
    Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
    Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
    Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 76. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
    Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
    Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
    Butler R; Hubner PJ
    Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 79. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Dillon WC; Eckert GJ; Dillon JC; Ritchie ME
    Catheter Cardiovasc Interv; 2000 Aug; 50(4):426-30. PubMed ID: 10931614
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
    Joseph T; Marco J; Gregorini L
    Clin Cardiol; 1998 Nov; 21(11):851-2. PubMed ID: 9825202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.